A Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity
What was tested
Treatment tested
- Orelabrutinib
Tyrosine-protein kinase BTK inhibitor
What it measured
Main measures
Cumulative number of new G+ T1 brain lesions at Week 12 (based on T1-weighted MRI scans at Weeks 4, 8, 12) compared to placebo.
MRI lesions
Other measures (1)
for the Core Part:
Papers
Loading reviews and guidelines…
Related trials
- REDIFINE MS
Recruiting
Still running
- FENerations1
Phase 2 · Recruiting
Still running
- CLOU064C12306
Phase 3 · Recruiting
Still running
- A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Pl…
Phase 2 · Withdrawn
Stopped early
- FENopta
Phase 2 · Running, not recruiting
Met its main goal
- Efficacy and safety of remibrutinib compared to terifluno…
Phase 3 · Ongoing
History
- In scope changed from true to false
Started
Jul 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error